GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » Notes Receivable

VIVUS (STU:VIU1) Notes Receivable : €0.00 Mil (As of Mar. 2020)


View and export this data going back to . Start your Free Trial

What is VIVUS Notes Receivable?

VIVUS's Notes Receivable for the quarter that ended in Mar. 2020 was €0.00 Mil.


VIVUS Notes Receivable Historical Data

The historical data trend for VIVUS's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS Notes Receivable Chart

VIVUS Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

VIVUS Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

VIVUS Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


VIVUS Notes Receivable Related Terms

Thank you for viewing the detailed overview of VIVUS's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


VIVUS (STU:VIU1) Business Description

Traded in Other Exchanges
N/A
Address
900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008
VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines